Reata Pharmaceuticals, Inc. - (RETA): Price and Financial Metrics
GET POWR RATINGS... FREE!
RETA POWR Grades
- Sentiment is the dimension where RETA ranks best; there it ranks ahead of 60.13% of US stocks.
- RETA's strongest trending metric is Value; it's been moving up over the last 31 weeks.
- RETA's current lowest rank is in the Momentum metric (where it is better than 11.83% of US stocks).
RETA Stock Summary
- The ratio of debt to operating expenses for Reata Pharmaceuticals Inc is higher than it is for about just 0.5% of US stocks.
- With a price/sales ratio of 587.27, Reata Pharmaceuticals Inc has a higher such ratio than 98.57% of stocks in our set.
- With a year-over-year growth in debt of -100%, Reata Pharmaceuticals Inc's debt growth rate surpasses just 0% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Reata Pharmaceuticals Inc are AKTS, UPLD, FEYE, UGRO, and MODN.
- Visit RETA's SEC page to see the company's official filings. To visit the company's web site, go to www.reatapharma.com.
RETA Stock Price Chart Interactive Chart >
RETA Price/Volume Stats
|Current price||$145.97||52-week high||$186.82|
|Prev. close||$146.01||52-week low||$76.34|
|Day high||$147.12||Avg. volume||367,726|
|50-day MA||$105.14||Dividend yield||N/A|
|200-day MA||$116.64||Market Cap||5.30B|
Reata Pharmaceuticals, Inc. - (RETA) Company Bio
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company was founded in 2002 and is based in Irving, Texas.
RETA Latest News Stream
|Loading, please wait...|
RETA Latest Social Stream
View Full RETA Social Stream
Latest RETA News From Around the Web
Below are the latest news stories about Reata Pharmaceuticals Inc that investors may wish to consider to help them evaluate RETA as an investment opportunity.
Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference
PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in a virtual Fireside chat and hold 1x1 meetings at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021. About Reata Pharmaceuticals, Inc. Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious
Shareholders Will Probably Not Have Any Issues With Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA) CEO Compensation
Shareholders may be wondering what CEO J. Huff plans to do to improve the less than great performance at Reata...
The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA filing.
Companies In The News Are: TGT, AMD, AZN, RETA
Reata Pharmaceuticals (RETA) has received a communication from the FDA stating that, after a preliminary review of briefing materials for an upcoming Type C meeting, a pre-NDA meeting is the most appropriate format for a discussion of the development program for omaveloxolone in Friedreich’s ataxia ((FA)).The Agency suggested that the...
RETA Price Returns
Continue Researching RETAWant to do more research on Reata Pharmaceuticals Inc's stock and its price? Try the links below:
Reata Pharmaceuticals Inc (RETA) Stock Price | Nasdaq
Reata Pharmaceuticals Inc (RETA) Stock Quote, History and News - Yahoo Finance
Reata Pharmaceuticals Inc (RETA) Stock Price and Basic Information | MarketWatch